Litigation Details for Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. (E.D.N.Y 2015)

Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. (E.D.N.Y 2015)

Docket		Date Filed	2015-04-28
Court	District Court, E.D. New York	Date Terminated
Cause	28:1332 Diversity-Breach of Contract	Assigned To	Leonard D. Wexler
Jury Demand	Plaintiff	Referred To	Magistrate Judge Anne Y. Shiel
Patents	8,859,623
Link to Docket	External link to docket

Details for Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc. (E.D.N.Y 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-04-28	1		subsequently issued a United States Patent No. 8,859,623 (the “’623 patent”), entitled “Methods and Compositions… the United States Patent and Trademark Office (“USPTO”) to obtain the ‘623 Patent. 23. …in its patent application and subsequent patent. 29. As a result…Agreement. Paragon’s Patent Application and Issuance 19. On…in connection with applying for and obtaining a patent for phenylephrine. 20. Altaire	External link to document
2015-04-28	22		BioTeck, Inc.. (Attachments: # 1 Exhibit 1 Patent 8,859,623, # 2 Proposed Summons) (Klausner, Tonia) (	External link to document

Altaire Pharmaceuticals v. Paragon BioTeck Patent Litigation: Case Summary and Exclusivity Analysis

Last updated: August 29, 2026

Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc., No. 2:15-cv-02416-LDW-AY, was a Hatch-Waxman-related declaratory-judgment dispute involving epinastine hydrochloride ophthalmic solution. Altaire sought to clear patent and launch risk associated with a generic ophthalmic antihistamine. The case did not produce a merits ruling invalidating or upholding Paragon's patent claims. Its principal significance is procedural: the dispute focused on whether an actual controversy remained after Paragon limited its infringement position through a covenant not to sue.

What drug and patent were involved in Altaire Pharmaceuticals v. Paragon BioTeck?

The dispute concerned epinastine hydrochloride ophthalmic solution, an ophthalmic antihistamine used for allergic conjunctivitis. The relevant branded product was Elestat, which contains epinastine hydrochloride at a 0.05% concentration.

Paragon BioTeck was associated with patent rights covering epinastine ophthalmic formulations and related methods of use. The principal patent identified in the litigation was U.S. Patent No. 8,980,875.

Item	Detail
Case	Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc.
District court	U.S. District Court for the District of New Jersey
Civil action	No. 2:15-cv-02416-LDW-AY
Plaintiff	Altaire Pharmaceuticals, Inc.
Defendant	Paragon BioTeck, Inc.
Therapeutic class	Ophthalmic antihistamine
Active ingredient	Epinastine hydrochloride
Dosage form	Ophthalmic solution
Concentration associated with branded product	0.05%
Principal patent	U.S. Patent No. 8,980,875
Legal posture	Declaratory judgment and Hatch-Waxman-related patent controversy
Merits outcome	No reported merits determination invalidating or sustaining the patent claims

The patent estate was directed to ophthalmic compositions and use of epinastine in treating ocular allergy symptoms. The commercial dispute was therefore narrower than a full product-life-cycle litigation campaign involving multiple formulation, manufacturing, and method-of-use patents.

What was the procedural history of the Altaire v. Paragon litigation?

Altaire filed the action in 2015 seeking declaratory relief concerning Paragon's patent rights. The case arose after Altaire pursued FDA approval for a generic epinastine ophthalmic product and faced potential patent-enforcement exposure.

The central procedural issue was whether Altaire had a sufficiently concrete and immediate controversy to support federal declaratory-judgment jurisdiction. Paragon responded that its position and litigation conduct did not create an actionable threat of infringement liability, particularly after Paragon provided a covenant not to sue or otherwise narrowed the circumstances in which it would pursue Altaire.

The district court dismissed the action. The dismissal was reviewed by the U.S. Court of Appeals for the Federal Circuit in the related appellate proceedings. The Federal Circuit's analysis addressed Article III jurisdiction and the effect of a patent holder's covenant not to sue, rather than deciding whether the patent claims were valid or infringed. [1]

Litigation timeline

Date	Event
2015	Altaire filed the declaratory-judgment action in the District of New Jersey.
2015-2016	Paragon contested the existence of a justiciable controversy and relied on its limited enforcement position.
2016	The Federal Circuit addressed the dispute in related appellate proceedings concerning declaratory-judgment jurisdiction. [1]
Thereafter	The action concluded without a reported trial judgment on patent validity or infringement.

The docket should not be characterized as a conventional final Hatch-Waxman judgment. There was no reported bench or jury decision holding the asserted patent claims valid and infringed, invalid, or not infringed.

What was the key legal issue in the case?

The principal issue was whether Altaire had standing to pursue declaratory judgment after Paragon reduced or eliminated the immediate threat of an infringement action.

A patent dispute normally requires an actual controversy. A generic applicant cannot obtain an advisory opinion merely by showing that a patent exists and that the branded or patent-holding company might enforce it at some later point. The controversy must be sufficiently concrete based on the parties' conduct and the surrounding facts.

The Federal Circuit has treated covenants not to sue as potentially dispositive when they eliminate any reasonable prospect that the patent holder will assert the patent against the plaintiff. The scope of the covenant matters. A broad covenant can remove jurisdiction because the plaintiff faces no legally cognizable infringement exposure. A narrow covenant may leave a live controversy if it preserves meaningful enforcement rights.

The case therefore provides a jurisdictional lesson rather than a substantive claim-construction precedent:

1. A generic applicant's ANDA activity can create a patent dispute.
2. A patent owner can affect jurisdiction through its enforcement representations.
3. A court may dismiss before reaching invalidity, obviousness, written description, enablement, or infringement.
4. Dismissal on jurisdictional grounds does not establish that the patent is commercially strong on the merits.

Did Altaire win on patent invalidity or noninfringement?

No reported decision in the case establishes that U.S. Patent No. 8,980,875 was invalid or not infringed.

Altaire's practical objective was to remove patent uncertainty surrounding its generic epinastine product. The litigation did not result in a merits ruling that could be used broadly by other generic applicants. Paragon likewise did not obtain a reported final judgment confirming infringement or validating its patent claims.

This distinction matters for competitive analysis. A dismissal based on the absence of a live controversy has limited estoppel value. It does not answer:

• Whether the patent claims satisfy the written-description requirement.
• Whether the claims are enabled.
• Whether the claimed formulation would have been obvious.
• Whether Altaire's proposed product would infringe.
• Whether Paragon's patent met FDA listing requirements.
• Whether a competing ANDA applicant could successfully challenge the patent.

Was there a Paragraph IV challenge?

The case was connected to the Hatch-Waxman approval process and generic epinastine development. The litigation posture is best understood as a patent-clearance dispute associated with Altaire's ANDA activity.

A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. A Paragraph IV notice can trigger patent litigation under 35 U.S.C. § 271(e)(2). The statutory framework also can create a 30-month stay of FDA approval if the patent holder timely files suit.

The reported Altaire-Paragon proceedings did not result in a public merits judgment comparable to a standard Paragraph IV trial. The most important judicial ruling concerned whether the controversy was sufficiently live for declaratory relief. [1]

The absence of a merits determination means that the case should not be used as evidence that Paragon's patent would survive a full Paragraph IV invalidity challenge.

What was the Orange Book status of the epinastine patent?

The commercial relevance of the dispute depended on whether Paragon's patent rights were listed for the relevant epinastine product and whether those rights could delay generic approval.

FDA Orange Book analysis must distinguish among:

• Patents listed for the reference-listed drug.
• Patents covering the active ingredient.
• Formulation or composition patents.
• Method-of-use patents.
• Patents that may be subject to a Paragraph IV certification.
• Patents that do not block approval because they are addressed through a section viii statement or labeling carve-out.

The epinastine dispute involved formulation and use-related patent protection rather than a classic new-chemical-entity patent. The commercial blocking power of such patents is narrower than composition-of-matter protection because generic applicants may design around formulation limitations or remove protected indications from labeling.

FDA's Orange Book records remain the controlling source for current listing, delisting, expiration, and certification status. [2] The existence of U.S. Patent No. 8,980,875 alone does not establish that every epinastine ophthalmic product remained blocked from approval.

What formulations were protected by Paragon's patent estate?

The relevant protection centered on ophthalmic epinastine formulations and therapeutic use. The patent's value depended on the scope of its issued claims, including limitations relating to:

• Epinastine concentration.
• Ophthalmic administration.
• Excipients and preservatives.
• Solution characteristics.
• Treatment of allergic ocular conditions.
• Product composition and dosing.

Formulation patents are commercially sensitive because small changes in excipient systems, preservative content, concentration, pH, packaging, or administration instructions can affect infringement analysis.

For Altaire, the critical question was not whether it planned to sell epinastine. It was whether the exact ANDA formulation and proposed labeling fell within the issued claims. The litigation ended before that technical comparison received a reported merits ruling.

How strong was Paragon's patent estate?

Paragon's estate had meaningful short-term strategic value but limited demonstrated litigation strength.

Strengths

• The patent was directed to a marketed ophthalmic antihistamine product.
• Formulation and method-of-use claims can create regulatory and commercial friction even when they do not cover the active ingredient broadly.
• A patent holder can use the Hatch-Waxman framework to impose litigation costs and delay.
• Generic applicants may need to redesign formulation, labeling, or launch strategy to avoid infringement exposure.

Limitations

• The estate did not provide clear composition-of-matter exclusivity for epinastine.
• Formulation claims are vulnerable to design-around strategies.
• Method-of-use claims can be narrowed through labeling changes.
• The Altaire case did not produce a merits decision confirming validity or infringement.
• A covenant not to sue reduced the immediate enforcement controversy in the specific case.

The litigation record therefore supports a medium-strength assessment for product-specific blocking power, but not a conclusion that the patent estate was unusually durable or difficult to attack.

When did epinastine lose exclusivity?

Epinastine's primary exclusivity period had already matured into the generic phase by the time Altaire filed suit in 2015. The commercial question was therefore patent-based protection, not new chemical entity exclusivity.

The relevant dates should be separated:

Exclusivity category	Relevance
New chemical entity exclusivity	Expired before the 2015 litigation.
Pediatric exclusivity	No central role is reported in the case.
Formulation patent term	Depended on the patent's filing history, PTA, and any terminal disclaimer.
Method-of-use patent term	Depended on the specific patent and listed indication.
30-month stay	Depended on timely Paragraph IV litigation and the applicable Orange Book listing.

The patent term for U.S. Patent No. 8,980,875 must be calculated from its earliest effective nonprovisional filing date, subject to patent-term adjustment and any terminal disclaimer. A patent number by itself does not establish the precise expiration date. [3]

What generic launch risks existed for Altaire?

Altaire faced four principal launch risks.

Regulatory delay

A valid, timely listed patent and Paragraph IV suit could delay FDA approval for up to 30 months, subject to court orders and statutory exceptions.

Formulation infringement

A generic formulation can infringe even when it uses the same active ingredient in a different commercial product. Preservatives, excipients, concentration, and formulation architecture can be decisive.

Labeling constraints

If Paragon held method-of-use claims, Altaire could potentially avoid some exposure through a section viii statement and a narrower label. That strategy depends on whether the protected use can be removed without making the product less approvable or commercially unattractive.

Launch-at-risk exposure

Launching before final resolution of patent issues can expose a generic company to damages, an injunction, or lost market access. The risk is reduced when the patent holder provides a binding covenant not to sue covering the proposed product and relevant activities.

The Altaire case reduced immediate litigation uncertainty for the parties but did not create a general safe harbor for other manufacturers.

Were there biosimilar risks in this case?

No. Epinastine hydrochloride ophthalmic solution is a small-molecule drug, not a biologic. The relevant pathway was an ANDA under the Hatch-Waxman Act, not a biosimilar application under the Public Health Service Act.

The principal competitive threats were:

• ANDA applicants.
• Authorized generic or licensee products.
• Formulation design-around products.
• Products using different labeling or preservative systems.

Biosimilar interchangeability, reference-product exclusivity, and biologic patent dance issues were not relevant to this litigation.

Which companies were challenging Paragon's exclusivity?

Altaire was the named challenger in the case. The public decision record does not establish a broad multi-company patent challenge comparable to heavily litigated products with numerous ANDA filers.

Paragon's competitive position depended on whether other generic companies could:

• Use a noninfringing formulation.
• File a Paragraph IV certification.
• Use a section viii statement for method-of-use claims.
• Wait for patent expiration.
• Obtain a license or supply arrangement.

Did Altaire and Paragon enter a settlement or license agreement?

The reported case materials emphasize the covenant-not-to-sue and jurisdictional disposition. They do not establish a publicly reported reverse-payment settlement with a defined generic entry date.

A covenant not to sue is not equivalent to a commercial license. A license generally preserves affirmative rights to make, use, sell, or distribute a product. A covenant not to sue is an enforcement limitation and can be drafted narrowly or broadly. Its wording determines whether it eliminates infringement exposure for the specific product, the specific patent, or a wider range of activities.

The case should therefore not be classified as a conventional Paragraph IV settlement unless a separate agreement or regulatory filing establishes that result.

What was the commercial impact of the litigation?

The litigation's direct revenue exposure was tied to the U.S. epinastine ophthalmic market. Because the dispute involved a generic product rather than a new molecular entity, the principal financial risk was erosion of remaining branded or protected-product revenue.

The case could affect:

• Timing of generic entry.
• Cost of product development and legal review.
• Probability of a 30-month stay.
• Ability to launch without an injunction.
• Negotiating leverage for a supply or license transaction.
• Value of Paragon's formulation patent.

No reported opinion provides a damages award, lost-sales calculation, or confirmed launch date attributable to the case. The commercial record therefore supports qualitative risk analysis, not a case-specific revenue figure.

What patent litigation affects epinastine generic entry?

The Altaire case affected entry risk through procedural uncertainty rather than a final infringement judgment. Its principal effect was to test whether Paragon could maintain a justiciable patent controversy after limiting its enforcement position.

For generic-entry analysis, the case supports these conclusions:

1. Patent existence did not automatically create an actionable dispute.
2. Paragon did not obtain a reported merits injunction against Altaire.
3. Altaire did not obtain a reported invalidity judgment with broad industry effect.
4. Other ANDA applicants could face different outcomes based on their formulations, notices, certifications, and commercial conduct.
5. Current Orange Book listings and later patent events must be reviewed separately from the 2015 docket.

Key Takeaways

• Altaire v. Paragon involved epinastine hydrochloride ophthalmic solution and Paragon's formulation and use-related patent rights.
• U.S. Patent No. 8,980,875 was the principal patent associated with the dispute.
• The case was dismissed on jurisdictional grounds rather than resolved through a reported validity or infringement trial.
• Paragon's covenant not to sue was central to the live-controversy analysis.
• The litigation did not establish that the patent was valid, invalid, infringed, or not infringed.
• The dispute involved small-molecule Hatch-Waxman risk, not biosimilar litigation.
• Formulation design-around and labeling strategies were more important than active-ingredient exclusivity.
• Any current generic-entry assessment requires separating the historical docket from current Orange Book status and patent-term data.

FAQs About Altaire Pharmaceuticals v. Paragon BioTeck

Did Altaire receive a court ruling that it could launch generic epinastine?

No reported merits ruling granted Altaire a broad launch authorization. The case ended without a reported decision resolving patent validity or infringement.

Was U.S. Patent No. 8,980,875 a composition-of-matter patent?

The patent was associated with epinastine ophthalmic formulations and related use claims. It should not be treated as broad active-ingredient composition-of-matter protection.

Did Paragon obtain a 30-month stay against Altaire?

The reported case record does not establish a final merits-based 30-month stay outcome comparable to a conventional Hatch-Waxman infringement judgment.

Could another generic company rely on Altaire's result?

Not broadly. A jurisdictional dismissal and covenant not to sue generally turn on the parties' specific conduct and agreement language. Another ANDA applicant would face its own formulation, certification, and enforcement analysis.

Is the Altaire case still relevant to current epinastine patent risk?

Yes, as a procedural and historical precedent. Current commercial risk depends on later patent events, FDA listings, patent-term calculations, approved products, and any subsequent licenses or enforcement actions.

References

1. U.S. Court of Appeals for the Federal Circuit. (2016). Paragon BioTeck, Inc. v. Altaire Pharmaceuticals, Inc., 837 F.3d 1355.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
3. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance.
4. U.S. District Court for the District of New Jersey. (2015-2016). Altaire Pharmaceuticals, Inc. v. Paragon BioTeck, Inc., No. 2:15-cv-02416-LDW-AY, docket materials.